Purple Biotech (PPBT) Income from Non-Controlling Interests (2017 - 2026)
Purple Biotech's (PPBT) quarterly Income from Non-Controlling Interests came in at $3000.0 in Q1 2026, little changed year-on-year from $3000.0 in Q1 2025, and down 96.91% on a QoQ basis from $97000.0 in Q4 2025.
Purple Biotech (PPBT) Income from Non-Controlling Interests (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 10 years of Income from Non-Controlling Interests data on file, last reported at $3000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests changed 0.0% year-over-year to $3000.0 in Q1 2026; TTM through Mar 2026 was $106000.0, a 360.87% increase from a year earlier, with the FY2025 full-year figure at -$106000.0, down 171.79% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at $3000.0, down from $97000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for PPBT reached as high as $97000.0 in Q4 2025 and fell as low as $2000.0 in Q3 2025.
- Historically, Income from Non-Controlling Interests has averaged $19823.5 across 5 years, with a median of $19000.0 in 2022.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 1840.0% in 2025 and fell as far as 84.21% in 2025.
- Year by year, Income from Non-Controlling Interests stood at $32000.0 in 2022, then declined by 3.12% to $31000.0 in 2023, then slumped by 83.87% to $5000.0 in 2024, then jumped by 1840.0% to $97000.0 in 2025, then tumbled by 96.91% to $3000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $3000.0 in Q1 2026, $97000.0 in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Purple Biotech | 1.33 Bn | 1.33 Bn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Dec 31, 2022 | 32,000.00 |
| Sep 30, 2022 | 25,000.00 |
| Jun 30, 2022 | 16,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Dec 31, 2021 | 46,000.00 |
| Sep 30, 2021 | 12,000.00 |
| Jun 30, 2021 | 16,000.00 |